Abstract: Inhibitor of apoptosis proteins (IAPs) are negative regulators of apoptosis. As IAPs are overexpressed in many tumors, where they confer chemoresistance, small molecules inactivating IAPs have been proposed as anticancer agents. Accordingly, a number of IAP-binding proapoptotic compounds that mimic the sequence corresponding to the N-terminal tetrapeptide of Smac/DIABLO, the natural endogenous IAPs inhibitor, have been developed. Here, we report the crystal structures of the BIR3 domain of cIAP1 in complex with Smac037, a Smac-mimetic known to bind potently to the XIAP-BIR3 domain and to induce degradation of cIAP1, and in complex with the novel Smac-mimetic compound Smac066. Thermal stability and fluorescence polarization assays show the stabilizing effect and the high affinity of both Smac037 and Smac066 for cIAP1-and cIAP2-BIR3 domains.
Introduction
The cellular process of apoptosis is essential for homeostasis maintenance in multicellular organisms, 1 being controlled by a subset of caspases (Cysteinedependent ASPartyl-specific proteASES) that are regulated, among others, by members of the IAP (Inhibitor of Apoptosis Proteins) family. 2, 3 Specific members of the IAP family, XIAP (X-chromosomelinked IAP), cIAP1 and cIAP2 (cellular IAPs), have been extensively investigated in the last few years and proposed as drug targets, as they are known to be abnormally expressed at high levels in the majority of human malignancies. 4 IAPs are composed of one to three tandem BIR (Baculoviral IAP Repeat) domains (BIR1-3) and of a C-terminal RING domain endowed with E3 ubiquitin ligase activity. It has been extensively reported that XIAP and cIAPs act differently: cIAP1 and cIAP2 participate in TNFainduced NF-jB activation, 5 whereas XIAP inhibits apoptosis binding to the initiator caspase-9 6 and to caspase-3 and -7 (executioner caspases), mainly via its BIR3 and linker-BIR2 domains. 7, 8 IAPs are endogenously antagonized by Smac/DIABLO (Second Mitochondria-derived Activator of Caspases/Direct IAp Binding with LOw pI) 9, 10 through the interaction of the N-terminal AVPI tetrapeptide of the latter with the BIR3 domains of IAPs. It has been recently shown that synthetic compounds based on the Smac N-terminal AVPI sequence [11] [12] [13] [14] [15] [16] can bind to the BIR domains of IAPs, relieving caspase binding through a competitive mechanism, thus promoting apoptosis. [17] [18] [19] [20] In addition, recent results have shown that
Smac-mimetic compounds can kill cancer cells by inducing the ''ubiquitin-dependent'' degradation of cIAP1 and cIAP2. 18, 19, 21 Starting from a synthetic compound proposed by Sun et al. 13 (Smac001, Fig. 1 : 20-fold more potent than the natural Smac AVPI peptide in binding the XIAP-BIR3 domain), we generated a library of 4-substituted azabicyclo [5.3 .0]alkane compounds displaying high BIR3 binding affinities. 16 In the last 2 years, Mastrangelo et al. 14 and Cossu et al. 15 carried over two studies based on X-ray crystallographic, simulative and functional data on the protein/ligand complexes formed by the BIR3 domain of XIAP and three different Smacmimetics (Smac005, Smac010, and Smac037) displaying different 4-substitutions (ACH 2 AOH, ACH 2 ANH þ 3 , and ACH 2 ACH 2 ANH þ 3 , respectively, see Fig. 1 ). These studies showed that, in relation to the different substituents, Smac037 displayed the highest affinity for XIAP-BIR3 and induced cIAP1 degradation in the MDA-MB231 cell line.
However, compared to other derivatives, Smac037 did not show optimal membrane permeability in in vitro profiling ADMET tests. 14 To enhance Smac037 lipophilicity, gain beneficial effects on cytotoxicity, and promote its intracellular uptake, Seneci et al. designed Smac066, 16 where a methyl group has been added to the terminal amine and the 4-substituent in the central ring has been further elongated to produce a more apolar arm (resulting in ACH 2 ACH 2 ANHACH 2 -Phenyl, Fig. 1 ). Smac066 presents low nanomolar potency on XIAP-linkerBIR2BIR3 and on the MDA-MB231 cell line, but also low micromolar potency on HL-60 and PC-3 cells. 16 This compound may thus represent an early lead to be further characterized and optimized in vitro and in vivo. Moreover, as several examples of bivalent Smac-mimetics that simultaneously bind to different BIRs of the same IAP molecule 12 have been reported as very potent pro-apoptotic agents (i.e., SM164), 22, 23 we also considered Smac066 4-substituent as a Smac-mimetics dimerization platform. In particular, the addition of a ACH 2 -Phenyl group, resembling the linker portion that joins the two SM164 mimic heads, allowed us to study a potential linker to produce bivalent molecules, in terms of rigidity patterns, possible binding ability, spacing characteristics, and bioavailability. Here, we characterize the binding affinity of four known Smac-mimetics (Smac001, 005, 010, and 037) together with Smac066 to the cIAP1-and cIAP2-BIR3 domains through fluorescence polarization assays. 22 Next, using thermal stability assays on both cIAP1-BIR3 and cIAP2-BIR3 domains, we explore the stabilization induced in both protein domains following the addition of Smac001, Smac005, Smac010, Smac037, and Smac066. Furthermore, we present the crystal structures of cIAP1-BIR3 in complex with Smac037 and with Smac066, highlighting details of the Smac-mimetics binding modes and validating hypotheses put forward by our previous molecular modelling/docking study. 15 Analysis of the crystal structures is presented at the light of the known binding mode of the AVPI tetrapeptide to the IBM (IAP Binding Motif) groove of cIAP1-BIR3 reported by Kulathila et al. 24 and of the ligand binding mode observed for the XIAP-BIR3/Smac037 complex. 15 Considering the structural conservation of the IBM groove in the BIR3 domains of cIAPs, and at the light of our thermal stability assays on cIAP2-BIR3, we finally tested in vitro the capabilities of Smac037 and Smac066 to induce cIAP1 and cIAP2 degradation in the MDA-MB231 cell line, as previously shown for cIAP1 after treatment with Smac005, 010, and 037. 15 
Results

Fluorescence polarization assays
Binding and displacement assays based on fluorescent polarization were used to evaluate the affinities of the synthesized Smac-mimetics for the cIAP1-and cIAP2-BIR3 domains. EC 50 values are reported in Table I .
We first performed two saturation binding experiments to determine the binding affinity of the fluorescent probe (Smac-5F) to cIAP1-and cIAP2-BIR3 domain. Under our experimental conditions, the K d values were evaluated as 4.8 6 0.6 nM for cIAP1-BIR3 and 23.6 6 1.6 nM for cIAP2-BIR3 (Fig.  2 , panel A), in agreement with the previous results by Lu et al. 22 Competitive binding assays revealed that all compounds tested displayed low nanomolar EC 50 values: Smac037 and Smac001 showed the greatest affinity for cIAP1-BIR3 and cIAP2-BIR3, compared to the other compounds of this series. The EC 50 value for Smac066 could not be obtained, because its affinity is too high relative to that of the fluorescent probe. Fig. 1 ). The presence of an elongated amino substituent in Smac037 yielded a more pronounced stabilizing effect on the XIAP-BIR3 domain relative to other reference Smac mimetic compounds.
Melting temperature shift assays
14 On the contrary, Smac037 higher stabilization was not observed for the BIR3 domain of cIAPs.
In detail, the cIAP1-BIR3 and the cIAP2-BIR3 isolated domains displayed a T m of 58.7 6 0.3 C and 49.1 6 0.8 C, respectively. Smac010 binding resulted in the minimum stabilization, with average DT m values of þ24.5 and þ21. 8 C when tested on cIAP1-and cIAP2-BIR3, respectively. Smac005 displayed the highest T m values among the compounds tested (average DT m values on three independent measurements of þ28.0 C for cIAP1-BIR3 and þ25.2 C for cIAP2-BIR3). Although the effects on T m are clear cut, suggesting that among the compounds tested on the cIAP1-and cIAP2-BIR3 domains, Smac037 and Smac066 do not represent the most stabilizing ligands (DT m shifts of þ25.8
C and þ24.6 C for cIAP1-BIR3/Smac037 and /Smac066, respectively, and þ21.9 C and þ20.8 C for cIAP2-BIR3/Smac037 and /Smac066, respectively), such assays must be taken only as a qualitative indication of their affinities for the different BIR domain constructs. Nevertheless, the T m data suggest that the positively charged 4-substituent (as in Smac010 and Smac037) is less effective than the ACH 2 OH substituent (of Smac005) in defining the Smac-mimetic affinity for cIAP1-and cIAP2-BIR3 domains, whereas the Smac066 4-substituent does not result in a significant stabilization effect when compared to the other Smac-mimetics tested (Table II) .
cIAP1-BIR3/Smac037 and /Smac066 complex structures
Analysis of the binding modes of Smac037 and Smac066 to cIAP1-BIR3 were addressed by X-ray crystallography based on crystals of the purified domain grown in the presence of the two Smac-mimetics. The 3D structures were solved through the molecular replacement method using as model the structure of cIAP1-BIR3 reported by Kulathila et al. 24 in complex with Smac-AVPI; the structures were refined at 2.6 Å and 3.0 Å resolution for cIAP1-BIR3/Smac037 and /Smac066, respectively (R gen and R free values together with refinement statistics are reported in Table III ). Both crystals display four molecules in the asymmetric unit. Each BIR3 domain is composed of six a-helices (a 1-2 at the N-terminus, and a 3-6 at the C-terminus) and a threestranded b-sheet; the structure is stabilized by a Zinc-finger motif, conserved in the homologous XIAP-BIR3 domain ( After molecular replacement, all BIR3 chains showed strong residual electron density in the IBM groove, comprised between the b3 strand and the a3 helix, roughly lined by residues Gly306, Arg308, Cys309, Glu311, Asp314, Glu319, and Trp323. Such residual electron density could be modelled and refined as bound Smac037 and Smac066 moieties (Fig. 3 , panels A and B). Also, about 11 amino acids in the C-terminal a helix, not present in the initial model of cIAP1-BIR3/Smac037 structure, were built during the refinement. When compared to the structure of Smac037 in complex with cIAP1-BIR3, the structure of cIAP1-BIR3 in presence of Smac066 It should be noticed that, in both crystal structures, crystal packing does not result in direct intermolecular contacts to any of the Smac-mimetic compounds, thus not affecting the binding mode of the Smac-mimetics to the cIAP1-BIR3 IBM pocket.
The cIAP1-BIR3/Smac-mimetics binding modes
As mentioned above, in all four chains of the crystal asymmetric unit, the ligand molecules are bound to the IBM groove, exchanging hydrogen bonds with main chain of residues Gly306, Arg308, and Cys309 (b3 strand) and salt bridges with the side chains of residues Glu311, Asp314, Glu319 (in b3-a3 loop and in a3). Trp323 is one of the most conserved residues within the IBM grooves of known IAP BIR3 domains. Its side chain has been shown to establish van der Waals interactions with the pyrrolidine ring of a conserved Pro in the IBMs of Smac/DIABLO and Caspase-9, and with the corresponding central ring moiety of the Smac-mimetic molecules reported so far in our 14, 15, 25 and other available structures of IAP complexes. 26, 27 Such interaction occurs also in the complex structures here presented (Fig. 3, C and  D) , where the side chain of cIAP1-BIR3 Trp323 stacks on the seven-carbon central ring of Smac037 and Smac066 (distances of 4.0 6 0.5 Å ). A second stacking interaction (p-cation interaction) is provided by Arg308, whose guanidine group is parallel to/and localizes at 3.9 6 0.3 Å from the Smac037 and Smac066 phenyl moiety adjacent to the cIAP1-BIR3 b3 strand (Fig. 3 , panels C and D). Details of all interactions stabilizing the cIAP1-BIR3/Smac037 and /Smac066 complexes are listed in Table IV and displayed in Fig. 3 , panels C and D. The cIAP1-BIR3/Smac-mimetics structures shed light on the role played by the 4-substituent groups (ACH 2 CH 2 NH þ 3 and ACH 2 CH 2 NHCH 2 Phenyl) relative to complex stabilization. Inspection of the cIAP1-BIR3/Smac037 crystal structure suggests that the 4-substituent affects the Smac-mimetic location due to a negative surface patch (Glu311, Asp314, Glu319) that attracts the two charged amino groups in the 4-substituent arm and in the N-terminal portion of Smac037. Such ''pulling effect'' is likely responsible for repositioning Smac037 in the IBM pocket relative to the XIAP-BIR3/Smac037 complex, 15 and may be one of the factors defining the lower melting temperatures measured for the cIAP1-BIR3/Smac010 and /Smac037 complexes (both bearing an amino 4-substituent) compared to cIAP1-BIR3/Smac001 and /Smac005 (Table II) . In fact, small shifts of Smac010 and Smac037 within the IBM groove may result in weaker b-like interactions with the BIR3 domain b3 strand, as discussed below. Although the long 4-substituent on Smac066 appears disordered in the solvent, we observed the same shift in the Smac-mimetic position within the BIR3 active pocket as in Smac037. In fact, at the crystallization pH both Smac066 N-methyl and the secondary amine in the 4-substituent ''arm'' are Table III . X-ray Data-Collection and Refinement Statistics for the cIAP1-BIR3/Smac037 and /Smac066 Complexes positively charged and thus subjected to the pooling effect of the protein negative patch. Such observation is in agreement with the similar thermal shift values observed for Smac37 and Smac66 ( DT m ¼ þ25.8 and þ24.6, respectively). Fluorescence polarization assays, however, show that Smac066 affinity for cIAP1-and 2-BIR3 domains remains very high, effectively exceeding the sensitivity limit of the FP technique. Such an effect could be due to a role played by the hydrophobic moiety on the Smac66 4-substituent arm that is not evident in our structural analysis.
Relative positioning of Smac037 and AVPI in the IBM groove of cIAP1
Inspection of the cIAP1-BIR3/Smac037 crystal structure here reported compared to that of the cIAP1-BIR3/Smac-AVPI complex (PDB code 3D9U) 24 shows a r.m.s. displacement of 0.38-0.48 Å (over 92 Ca pairs); according to expectations, the protein/peptide mimetic and the protein/peptide interactions are closely similar in the two complexes (Fig. 4, panel  A) . Specific interactions gained or lost in the cIAP1-BIR3/Smac037 binding mode, when compared to the BIR3/AVPI complex are summarized in Table IV . In general, there is an overall shift of Smac037 relative to AVPI toward the negative patch, mentioned above (about 0.5 Å ), but also away from the b3 strand (about 0.8 Å ). These shifts are probably due to a concerted effect of a ''pulling action'' on the positive charges of Smac037 by the negative patch of the IBM groove, and of a ''pushing effect'' provided by Trp310 toward the Smac037 N-terminal ethyl moiety. In fact, such ethyl substituent of Smac037 is bulkier than the Ala side chain in AVPI, potentially resulting in a collision with the side chain of Trp310 Cossu et al.
that would require a 0.8 Å displacement to be released.
Relative positioning of Smac037 in the IBM groove of cIAP1 and XIAP
The binding mode of Smac037 to cIAP1-BIR3 is also similar to that observed for the same ligand on XIAP-BIR3 (Fig. 4, panel B) . In fact, the XIAP-BIR3 residues involved in van der Waals contacts (Val298, Lys299, and Trp310) and hydrogen bonds (Gly306, Leu307, and Trp323) with the inhibitory compounds are conserved, except for Leu292, replaced by Val in cIAPs; XIAP Glu314 is conservatively substituted with Asp in cIAP1, while Gln319 is Glu319 in cIAP1 (and Gln319 in cIAP2). Finally, residues Thr308 and Asp309 that were found relevant for the interaction of XIAP-BIR3 with the Smac-mimetics are replaced in cIAPs by Arg308 and Cys309 (Fig. 4, panel C) . As expected, the hydrogen bonds that involve the cIAP1-and XIAP-BIR3 b3 backbone are generally maintained, with significant variations concerning the residues belonging to the b3-a3 loop. First, the presence of Asp314 in cIAP1 (Glu314 in XIAP) causes the sliding of Smac037 toward such residue (and toward the cIAP1 negative patch Glu311, Asp314, and Glu319, which in XIAP hosts Lys311, Glu314 and Gln319, respectively) to establish optimal electrostatic interactions (Fig. 4, panel B) . Besides, the nonconservative substitution of XIAP-BIR3 Lys311 with Glu311 in cIAP1-BIR3 makes the negative pocket more attractive compared to the XIAP-BIR3 homologous patch, where the Smac-mimetic shift is not observed.
In conclusion, although the Smac037 interaction network is generally conserved among the two BIR3 domains, there are some amino acid substitutions that, on the whole, slightly weaken Smac037 binding to cIAP1-BIR3 relative to XIAP-BIR3, shifting the ligand of about 1.5 Å toward the negative patch described.
cIAPs degradation by Smac-mimetics in MDA-MB231 cell line
Although apoptotic regulation is performed differently by XIAP and cellular IAPs, these members of the IAP family are structurally homologous. XIAP shows an amino acid sequence identity to cIAP1 and cIAP2 of 36% and 39%, respectively, whereas the amino acid sequence identity between cIAP1 and cIAP2 is 70%. In particular, the region of BIR3 domain, where are located the critical residues involved in Smac-mimetics recognition, is well conserved among the three IAPs analyzed (Fig. 4, panel  C) . As a consequence of such prominent structural conservation, Smac-mimetics are shown to be broadly effective on the most characterized members of the IAP family: they mimic Smac/DIABLO in preventing XIAP inhibition of initiator and effector caspases, and in parallel they can kill malignant cells by inducing auto-degradation of cIAP1 and cIAP2, thus leading to TNF-receptor mediated apoptosis. 18, 19, 21 The melting temperature shifts of cIAP1-and cIAP2-BIR3 induced by the Smac-mimetic compounds here considered and the crystal structures provide evidence of efficient Smac-mimetic binding to the target proteins, that result in XIAP seizure and cIAPs auto-ubiquitination. Based on the high amino acid sequence conservation of the three IAP family members, in particular between cIAP1-BIR3 and cIAP2-BIR3 (Fig. 4, panel C) , we speculated that the Smac-mimetics here discussed could also bind to the cIAP2-BIR3 domain. For this reason, we tested in vitro the effects of Smac037 and of Smac066 in inducing both cIAPs degradation in the MDA-MB-231 cell line, as previously reported for the cIAP1-BIR3 domain after cell treatment with Smac005, 010, and 037. 15 The Western blot analysis showed that Smac037 and 066 effectively induce the degradation of cIAP1 15 but not completely that of cIAP2 (Fig. 4, panel D) . In fact, it has been shown that abrogation of Smac-mimetics-induced apoptosis can occur by upregulation of cIAP2, which although initially degraded, is refractory to subsequent degradation. 28 This suggests that cIAP2 may require the presence of cIAP1 for its own ubiquitination, like ; on the other hand, cIAP1 degradation induced by Smac-mimetics may prevent the complete removal of cIAP2, whose upregulation may result in the long-term restoration of cellular IAPs activity. These results, together with the structural details of the cIAP1-BIR3/Smac037 and cIAP1-BIR3/ Smac066 complexes, provide new hints for the development of lead compounds able to bind XIAP, cIAP1, and cIAP2, thus acting in different apoptotic pathways.
Discussion
IAPs are crucial players in the major apoptotic pathways, and their blockade seems to be one of the most promising strategies for tumor suppression. The identification of lead compounds mimicking the natural antagonist of IAPs, Smac/DIABLO, is now the focus of extensive research, as it has been broadly reported that Smac-mimetics induce apoptosis in many neoplastic cell lines, especially in combination with other chemioterapics, as recently reported by Lecis et al. 30 for melanoma cell line. The
Smac-mimetics proposed in this study present high affinity for cIAP1-and 2-BIR3 in fluorescence binding assays and high stabilization ability on the protein construct tested, suggesting enhanced capability to specifically recognize the active pockets on the target IAP proteins. The crystal structures here described provide new ideas for the design of more potent drug leads, which can be accurately developed for the BIR3 domains of XIAP and cIAP1. In particular, the small number of amino acid differences in IAPs BIR3 highlight three regions in the Smac-mimetic compounds that can be exploited to modulate affinity for the diverse proteins.
(1) Smacmimetic phenyl end: the p-cation interaction with Arg308 in cIAPs is not present in XIAP (substituted by Thr309), and the hydrophobic cavity hosting the phenyl moiety is smaller in cIAPs (lined by Val292) than in XIAP (Leu292). (2) Smac-mimetic 4-substituent arm: it is possible to modulate its interaction with amino acid 309 (Cys in cIAPs and Asp in XIAP). (3) Smac-mimetic N-terminal end interacts with the IBM negative patch that is wider and more charged in cIAPs than in XIAP. As a general consequence, referring to points 1 and 3, we can speculate that a limited extension of a Smac-mimetic compound both at its phenyl and N-terminal ends could maintain its affinity for cIAPs-BIR3, reducing that for XIAP. In addition, as bivalent Smac-mimetic molecules have been reported as very potent agents on tumors, 22 mobile noninteractive portions of the Smac-mimetics could be elongated to allow the design of bivalent compounds, simultaneously targeting different BIR domains of the same IAP. In this context, the addition of Smac066 4-substituent 16 could be a useful tool to begin the characterization of different linkers joining two Smac-mimetic heads.
In particular, a noninteractive linker would be preferable, to favor the Smac-mimetic/IBM groove interactions only and avoid secondary binding motives that would produce an impairment of the usual IAPs-Smac-mimetics recognition. In the cIAP1-BIR3/ Smac066 structure here reported, the Smac066 4-substitution meets such requirement, being free in the solvent and exposed enough to be linked to a second Smac-mimetic molecule. Although the crystal packing here observed may not be consistent with the real distances between the BIR of the same IAP molecule, and with their relative positions, the structure here described provides general ideas on how to join two Smac-mimetic heads, to be subsequently tested in a wider drug design study. All the efforts in Smac-mimetics optimization rely on the fact that they are versatile compounds, acting on different IAP members that are involved in distinct apoptotic pathways; these small molecules competitively bind to the IBM pocket of XIAP, preventing caspase inhibition, and induce cIAPs degradation, as shown here. Although the former activity has been extensively described, the molecular mechanism by which Smac-mimetics produce cIAPs auto-ubiquitination has not been defined yet. In this context, further structural and functional characterization of the full length cIAP proteins may be of prime interest.
Materials and Methods
Chemistry
All the Smac-mimetics were synthesized following the procedures described. 14, 15 The chemical procedure for Smac066 synthesis and the rational bases for its design are reported by Seneci et al., 16 where Smac066 is named as ''40d.'' Smac037 and Smac066 were suspended in water at a final concentration of 0.1M.
Cloning, expression, and purification of human cIAP1-BIR3
The sequence coding for cIAP1-and cIAP2-BIR3 domains residues 245-357 (XIAP-BIR3 structural homology numbering) were cloned in pET21(a) vector (Novagen) with a C-terminal 6xHis-tag. The plasmids were used to transform Escherichia coli strain BL21(DE3). The recombinant proteins were purified using Ni-NTA (His-trap FFcrude, GeHealthcare), followed by gel filtration (Superdex 200, Ge-Healthcare). The recombinant proteins were eluted in 20 mM Tris pH 8.0, 250 mM NaCl, and 10 mM DTT, and cIAP1-BIR3 was concentrated to 10 mg mL À1 for crystallization tests using an Amicon Ultra centrifugal filter (10 kDa cut-off).
Fluorescence polarization assays
Fluorescence polarization experiments were performed according to Lu et al. 22 Briefly, the fluorescently labelled Smac peptide SM5F (AbuRPF-K(5-Fam)-NH 2 , final concentration of 2 nM), and increasing concentrations of cIAP1-and cIAP2-BIR3 from 0 to 20 lM, were added to an assay buffer consisting of 100 mM potassium phosphate, pH 7.5, 100 lg/mL bovine c-globulin, 0.02% sodium azide. After shaking (15 min), the plate was incubated for 3 h at room temperature. Fluorescence polarization was measured on an Ultra plate reader (Tecan), at excitation and emission wavelengths of 485 nm and 530 nm, respectively. The equilibrium binding curves were drawn by plotting experimental data (millipolarization units, mP) as a function of recombinant concentration. All experiments were performed in black, flat-bottom 96-well microplates (Greiner bio-one). Table I .
Melting temperature shift assays
To monitor protein unfolding, the fluorescent dye Sypro Orange, an environmentally sensitive dye, was used. The fluorescence intensity increases during protein unfolding because the fluorescent dye binds efficiently to the unfolded protein, and displays a higher quantum yield in a lower dielectric environment. The melting temperatures are calculated as the maximum in the first derivative of the recorded sigmoid. The overall continuous decrease of the fluorescence intensity, after unfolding, is due to dye decay and, likely, to aggregation of the denatured protein-dye complexes. 31 Thermal shift assays for the different Smacmimetics were conducted in a MiniOpticon RealTime PCR Detection System (Bio-Rad). Solutions of 2.2 lL of the cIAP1 or cIAP2 BIR protein were mixed with 3.5 lL of Sypro orange (Sigma) diluted 1:60, 19 lL of the respective buffers, and 0.3 lL of 50 mM Smac-mimetics (Smac001, Smac005, Smac010, Smac037, and Smac066). Distilled water was added in place of the inhibitors for the control samples. The final protein concentrations ranged between 0.4 and 0.5 mg/mL; the sample plates were heated from 4 to 99 C, with a heating rate of 0.2 C/5 sec. Fluorescence intensity was measured within the excitation/emission ranges 470-505/540-700 nm. All the experiments were performed in triplicate to produce an average T m value and an error estimation (Table II) .
Crystallization and crystallographic data reduction
Sitting drop crystallization experiments were prepared using an Oryx-8 crystallization robot (Douglas Instruments, East Garston, UK), from a 2:1 mixture of the protein stock solution (provided with 5 mM of Smac037 and of Smac066) and the precipitant solution to a final drop volume of 0.3 lL for the initial screenings and of 0.5 lL for the optimization trials. After 4 days of vapour diffusion at 20 C, one irregular globular crystal of cIAP1-BIR3 in complex with Smac037 of $80 lm 3 was obtained in 25% PEG 3350, 0.1M Hepes pH 7.5 and 0.2M Lithium Sulphate. A prismatic crystal for the complex cIAP1-BIR3/Smac066 was obtained after 4 days of vapor diffusion at 20 C in 25% PEG 3350, 0.1M Tris, pH 8.0, and 0.1M Sodium Citrate. Before being freshcooled in liquid nitrogen, the crystal for the cIAP1-BIR3/Smac037 was soaked in paraffin, whereas the crystal of the complex with Smac066 was harvested in a cryoprotectant solution (25% PEG 400, 0.1M Tris, pH 8.0, 0.1M Sodium Citrate and 25% glycerol). The crystals diffracted to a maximum resolution of 2.6 Å for the complex with Smac037 and of 3.0 Å for Smac066, using synchrotron radiation on beam-line ID 14-4, at the European Synchrotron Radiation Facility (ESRF-Grenoble, France). The diffraction data were processed with MOSFLM, 32 and intensities were merged using SCALA. 33 Structure determination and refinement
The cIAP1-BIR3/Smac037 and /Smac066 crystals belong to the C2 and C222 space groups with unit cell parameters a ¼ 71.4, b ¼ 79.7, c ¼ 98.3 Å (Smac037 complex) and a ¼ 113.6, b ¼ 114.6, c ¼ 92.9 Å (Smac066 complex); in both cases, there are four protein molecules in the crystal asymmetric unit (V M ¼ 2.5 Å 3 Da À1 , 51% solvent content for both complexes). 34 The crystal structure was solved with molecular replacement (molrep 35 ), using the structure of the BIR3 domain in the cIAP1-BIR3/SmacAVPI complex (PDB code 3D9U 24 ) as search model. The four independent molecules were subjected to rigid-body refinement (R/Rfree ¼ 42.0/41.3 for the cIAP1-BIR3/ Smac037 complex, R/R free ¼ 42.2/44.6 for the cIAP1-BIR3/Smac066), and subsequently refined using REFMAC5. 36 A random set comprising 5% of the data was omitted from refinement for R-free calculation. Manual rebuilding 37 and additional refinement 38 were subsequently performed. Inspection of difference Fourier maps at this stage showed strong residual density, located between the a3 helix and the main bsheet, compatible with one Smac-mimetic inhibitor for each molecule in the asymmetric unit, which was accordingly model-built. The last refinement cycles have been performed using program Buster 38 with TLS (Translation Libration Screw-motion) and NCS (Non crystallographic symmetry) restrains. The refined cIAP-BIR3/Smac037 and /Smac066 models display almost the entire amino acid chain; the first 12 N-terminal residues (241-253) and the last 2 C-terminal residues are disordered. Data collection and refinement statistics are summarized in Table I . The stereochemical quality of the models was checked using the program Procheck 39 and is summarized in the Table I . Atomic coordinates and structure factors for cIAP1-BIR3/Smac037 and / Smac066 complexes have been deposited with the Protein Data Bank 40 with accession codes 3MUP
and 3OZ1, respectively.
IAP degradation cell-based assays
The MDA-MB231 cell line was treated with 5 lM of Smac037 or Smac066, or left untreated as control. After 3 h, cells were harvested and lysed. Proteins were revealed by Western blot using antibodies specific for XIAP (BD Biosciences), cIAP1 and cIAP2 (R&DSystems), and bActin (Sigma) as control.
